Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Impact of licensing and reimbursement discrepancies on cancer care in Europe and Canada

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 713

Jan McKendrick - PRMA Consulting Ltd, Fleet, UK

Jan McKendrick speaks with ecancer at ESMO 2017 an investigation into the availability of cancer therapies across Europe and Canada, depending on different licensing and reimbursement processes.

She describes how discord in national and international regulation, or communication of regulations, exposes thousands of patients every year to inadequate treatment, and goes on to consider the role of clinicians in preventing patients falling through legislative gaps.

Read more about these findings here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence